The clinical outcomes of patients with portal vein tumor thrombi after living donor liver transplantation

Ho Joong Choi, Dong Goo Kim, Gun Hyung Na, Tae Ho Hong, Si Hyun Bae, Young Kyoung You, Jong Young Choi, Seung Kew Yoon – 8 May 2017 – The purpose of this study was to evaluate the feasibility of living donor liver transplantation for treatment of patients with hepatocellular carcinoma and segmental portal vein tumor thrombus (PVTT) below the second‐order branch. Between January 2005 and December 2015, we retrospectively analyzed 242 patients in a control group (n = 184), a microvascular invasion (MVI) group (n = 24), and a PVTT group (n = 34).

Tips and pitfalls in direct ligation of large spontaneous splenorenal shunt during liver transplantation

Hyeyoung Kim, Kyung Chul Yoon, Kwang‐Woong Lee, Nam‐Joon Yi, Hae Won Lee, YoungRok Choi, Dongkyu Oh, Hyo‐Sin Kim, Suk Kyun Hong, Sung Woo Ahn, Kyung‐Suk Suh – 8 May 2017 – Patients with large spontaneous splenorenal shunts (SRSs) prove challenging during liver transplantation (LT), regardless of organizing portal vein (PV) thrombosis. Here, we detail the clinical outcomes of 26 patients who underwent direct ligation of large SRSs during LT. Direct ligation of large SRS was applied in poor portal flow during LT.

How healthy are the “Healthy volunteers”? Penetrance of NAFLD in the biomedical research volunteer pool

Varun Takyar, Anand Nath, Andrea Beri, Ahmed M. Gharib, Yaron Rotman – 3 May 2017 – Healthy volunteers are crucial for biomedical research. Inadvertent inclusion of subjects with nonalcoholic fatty liver disease (NAFLD) as controls can compromise study validity and subject safety. Given the rising prevalence of NAFLD in the general population, we sought to identify its prevalence and potential impact in volunteers for clinical trials. We conducted a cross‐sectional study of subjects who were classified as healthy volunteers between 2011 and 2015 and had no known liver disease.

Acetyl‐coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double‐blind, crossover study

Kathryn Stiede, Wenyan Miao, Heather S. Blanchette, Carine Beysen, Geraldine Harriman, H. James Harwood, Heather Kelley, Rosana Kapeller, Tess Schmalbach, William F. Westlin – 3 May 2017 – NDI‐010976, an allosteric inhibitor of acetyl‐coenzyme A carboxylases (ACC) ACC1 and ACC2, reduces hepatic de novo lipogenesis (DNL) and favorably affects steatosis, inflammation, and fibrosis in animal models of fatty liver disease.

Subscribe to